Emory University Stake in Puma Biotechnology (PBYI) Has Lowered by $344,078 as Stock Declined; Cognex (CGNX) Market Value Declined While Northstar Asset Management Boosted Stake by $807,640

May 14, 2018 - By Adrian Mccoy

Cognex Corporation (NASDAQ:CGNX) Logo

Emory University decreased its stake in Puma Biotechnology Inc (PBYI) by 17.08% based on its latest 2017Q4 regulatory filing with the SEC. Emory University sold 3,511 shares as the company’s stock declined 33.20% with the market. The institutional investor held 17,044 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $1.69 million, down from 20,555 at the end of the previous reported quarter. Emory University who had been investing in Puma Biotechnology Inc for a number of months, seems to be less bullish one the $2.01 billion market cap company. The stock increased 2.61% or $1.35 during the last trading session, reaching $53.15. About 1.29 million shares traded or 57.14% up from the average. Puma Biotechnology, Inc. (NYSE:PBYI) has risen 66.84% since May 14, 2017 and is uptrending. It has outperformed by 55.29% the S&P500.

Northstar Asset Management Llc increased its stake in Cognex Corporation (CGNX) by 109.88% based on its latest 2017Q4 regulatory filing with the SEC. Northstar Asset Management Llc bought 13,240 shares as the company’s stock declined 13.83% with the market. The institutional investor held 25,290 shares of the industrial machinery and components company at the end of 2017Q4, valued at $1.55M, up from 12,050 at the end of the previous reported quarter. Northstar Asset Management Llc who had been investing in Cognex Corporation for a number of months, seems to be bullish on the $8.37B market cap company. The stock decreased 0.21% or $0.1 during the last trading session, reaching $48.37. About 1.20 million shares traded. Cognex Corporation (NASDAQ:CGNX) has risen 31.99% since May 14, 2017 and is uptrending. It has outperformed by 20.44% the S&P500.

Among 19 analysts covering Cognex Corporation (NASDAQ:CGNX), 9 have Buy rating, 3 Sell and 7 Hold. Therefore 47% are positive. Cognex Corporation had 47 analyst reports since August 4, 2015 according to SRatingsIntel. Robert W. Baird maintained Cognex Corporation (NASDAQ:CGNX) on Tuesday, May 1 with “Neutral” rating. The rating was downgraded by Northcoast to “Neutral” on Friday, December 2. J.P. Morgan downgraded the stock to “Sell” rating in Monday, May 7 report. The stock of Cognex Corporation (NASDAQ:CGNX) has “Buy” rating given on Friday, September 8 by Cowen & Co. The rating was maintained by Canaccord Genuity with “Hold” on Tuesday, August 2. The firm earned “Outperform” rating on Tuesday, November 3 by Credit Agricole. The rating was downgraded by CLSA on Tuesday, November 3 to “Outperform”. As per Tuesday, October 31, the company rating was maintained by Robert W. Baird. The firm earned “Underperform” rating on Thursday, March 24 by CSLA. The rating was downgraded by Goldman Sachs on Tuesday, April 10 to “Hold”.

More notable recent Cognex Corporation (NASDAQ:CGNX) news were published by: Prnewswire.com which released: “The Rise of the Robot: Investing in Disruptive Automation” on May 14, 2018, also Seekingalpha.com with their article: “Will Cognex Stock Keep Falling?” published on May 09, 2018, Streetinsider.com published: “Pre-Open Movers 05/01: (INGN) (KPTI) (NTRI) Higher; (IVAC) (CGNX) (KLXI) Lower (more…)” on May 01, 2018. More interesting news about Cognex Corporation (NASDAQ:CGNX) were released by: Nasdaq.com and their article: “Factors of Influence in 2018, Key Indicators and Opportunity within Cognex, MRC Global, Fulton Financial, Synovus …” published on May 14, 2018 as well as Seekingalpha.com‘s news article titled: “Cognex Corporation’s (CGNX) CEO Robert Willett on Q1 2018 Results – Earnings Call Transcript” with publication date: May 01, 2018.

Northstar Asset Management Llc, which manages about $241.97 million US Long portfolio, decreased its stake in Celgene Corporation (NASDAQ:CELG) by 9,295 shares to 11,925 shares, valued at $1.25M in 2017Q4, according to the filing.

Since March 12, 2018, it had 0 insider buys, and 1 sale for $564,892 activity.

Investors sentiment increased to 6.53 in Q4 2017. Its up 5.48, from 1.05 in 2017Q3. It increased, as 32 investors sold CGNX shares while 21 reduced holdings. 84 funds opened positions while 262 raised stakes. 268.44 million shares or 268.52% more from 72.84 million shares in 2017Q3 were reported. Hermes Mgmt Limited has invested 1.19% in Cognex Corporation (NASDAQ:CGNX). M&T National Bank Corporation invested in 0.01% or 41,527 shares. Gilder Gagnon Howe And, New York-based fund reported 632,128 shares. Envestnet Asset Mngmt has 58,080 shares. Copeland Capital Ltd Liability Corp owns 42,542 shares for 0.16% of their portfolio. Winslow Evans & Crocker Inc invested 0.14% of its portfolio in Cognex Corporation (NASDAQ:CGNX). Korea Investment Corporation reported 10,800 shares. Brown Limited Liability Corporation holds 5% or 6.74 million shares. Ledyard Natl Bank invested in 0% or 214 shares. Mitsubishi Ufj & Bk owns 353,949 shares. California Pub Employees Retirement has 0.04% invested in Cognex Corporation (NASDAQ:CGNX). Oregon Public Employees Retirement Fund has invested 0.06% in Cognex Corporation (NASDAQ:CGNX). Bluestein R H And reported 0.02% stake. 520 are held by Hall Laurie J Trustee. Stratos Wealth Ptnrs Limited holds 1,452 shares or 0% of its portfolio.

Since January 22, 2018, it had 0 buys, and 4 insider sales for $1.40 million activity. Lo Steven had sold 1,858 shares worth $172,515 on Monday, January 22. 1,860 shares were sold by BRYCE RICHARD PAUL, worth $172,515 on Monday, January 22. $991,683 worth of Puma Biotechnology, Inc. (NASDAQ:PBYI) was sold by AUERBACH ALAN H.

Among 11 analysts covering Puma Biotechnology Inc (NYSE:PBYI), 8 have Buy rating, 0 Sell and 3 Hold. Therefore 73% are positive. Puma Biotechnology Inc had 61 analyst reports since August 27, 2015 according to SRatingsIntel. The stock has “Outperform” rating by Cowen & Co on Thursday, May 25. Cowen & Co maintained Puma Biotechnology, Inc. (NASDAQ:PBYI) on Monday, June 5 with “Buy” rating. The stock of Puma Biotechnology, Inc. (NASDAQ:PBYI) has “Buy” rating given on Thursday, July 6 by Stifel Nicolaus. The company was downgraded on Wednesday, January 24 by Cowen & Co. The firm earned “Outperform” rating on Friday, November 10 by Credit Suisse. The stock of Puma Biotechnology, Inc. (NASDAQ:PBYI) earned “Buy” rating by Citigroup on Tuesday, March 29. The firm has “Buy” rating given on Friday, November 10 by Citigroup. The firm earned “Buy” rating on Tuesday, May 23 by Stifel Nicolaus. The stock of Puma Biotechnology, Inc. (NASDAQ:PBYI) has “Buy” rating given on Wednesday, January 24 by Bank of America. RBC Capital Markets maintained the shares of PBYI in report on Wednesday, October 25 with “Hold” rating.

More news for Puma Biotechnology, Inc. (NASDAQ:PBYI) were recently published by: 247Wallst.com, which released: “Breast Cancer Drug Can Bring Exponential Sales Growth for Puma Biotechnology” on April 17, 2018. Benzinga.com‘s article titled: “Benzinga’s Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway” and published on May 09, 2018 is yet another important article.

Investors sentiment increased to 1.65 in Q4 2017. Its up 0.10, from 1.55 in 2017Q3. It improved, as 13 investors sold PBYI shares while 50 reduced holdings. 40 funds opened positions while 64 raised stakes. 34.70 million shares or 2.80% less from 35.70 million shares in 2017Q3 were reported. Huntington Commercial Bank has 0% invested in Puma Biotechnology, Inc. (NASDAQ:PBYI). Barclays Public Ltd Limited Liability Company invested 0% in Puma Biotechnology, Inc. (NASDAQ:PBYI). Federated Pa has 75,853 shares for 0.02% of their portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) stated it has 0% in Puma Biotechnology, Inc. (NASDAQ:PBYI). Tru Commerce Of Vermont holds 0% in Puma Biotechnology, Inc. (NASDAQ:PBYI) or 100 shares. State Of Wisconsin Board invested 0.01% of its portfolio in Puma Biotechnology, Inc. (NASDAQ:PBYI). Voya Investment Mgmt Ltd Liability Co holds 253,007 shares. Credit Suisse Ag holds 0% or 35,052 shares. Citadel Advisors Lc holds 0.05% of its portfolio in Puma Biotechnology, Inc. (NASDAQ:PBYI) for 836,925 shares. Dupont Cap Mgmt has 5,977 shares. Grp One Trading Limited Partnership stated it has 0.03% of its portfolio in Puma Biotechnology, Inc. (NASDAQ:PBYI). Sio Cap Mgmt accumulated 12,209 shares. Eagle Asset Management holds 297,620 shares. Legal General Group Public Ltd Com holds 0% or 12,688 shares in its portfolio. Meeder Asset Mgmt stated it has 0% of its portfolio in Puma Biotechnology, Inc. (NASDAQ:PBYI).

Emory University, which manages about $116.54 million US Long portfolio, upped its stake in Biohaven Pharmactl Hldg Co L by 16,440 shares to 74,378 shares, valued at $2.01M in 2017Q4, according to the filing. It also increased its holding in Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) by 47,154 shares in the quarter, for a total of 170,404 shares, and has risen its stake in Dbv Technologies S A.

Puma Biotechnology, Inc. (NASDAQ:PBYI) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>